[go: up one dir, main page]

BR0100949A - Inibição da degradação oxidativa de formulaçõesfarmacêuticas - Google Patents

Inibição da degradação oxidativa de formulaçõesfarmacêuticas

Info

Publication number
BR0100949A
BR0100949A BR0100949-4A BR0100949A BR0100949A BR 0100949 A BR0100949 A BR 0100949A BR 0100949 A BR0100949 A BR 0100949A BR 0100949 A BR0100949 A BR 0100949A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulations
inhibition
oxidation
pharmaceutical
oxidative degradation
Prior art date
Application number
BR0100949-4A
Other languages
English (en)
Inventor
Hai Wang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0100949A publication Critical patent/BR0100949A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/06—Chelate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "INIBIçãO DA DEGRADAçãO OXIDATIVADE FORMULAçõES FARMACêUTICAS". A invenção fornecemétodos para inibir a degradação oxidativa de formulaçõesfarmacêuticas compreendendo pelo menos um ingrediente dedroga ativo suscetível de oxidação, cujos métodos compreendema adição de uma quantidade inibidora da oxidação de uma fontede íon ferroso, preferivelmente na forma de um excipientefarmacêutico, à formulação. A invenção fornece ainda formulaçõesfarmacêuticas compreendendo pelo menos um ingredientefarmacêutico ativo suscetível de oxidação, e uma quantidadeinibidora da oxidação de uma fonte de íon ferroso, preferivelmentena forma de um excipiente farmacêutico. A invenção fornece aindao uso de uma fonte de íon ferroso como um antioxidante deformulações farmacêuticas.
BR0100949-4A 2000-03-10 2001-03-09 Inibição da degradação oxidativa de formulaçõesfarmacêuticas BR0100949A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18844700P 2000-03-10 2000-03-10

Publications (1)

Publication Number Publication Date
BR0100949A true BR0100949A (pt) 2001-10-30

Family

ID=22693191

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0100949-4A BR0100949A (pt) 2000-03-10 2001-03-09 Inibição da degradação oxidativa de formulaçõesfarmacêuticas

Country Status (5)

Country Link
US (2) US6423351B2 (pt)
EP (1) EP1145719A3 (pt)
JP (1) JP2001261577A (pt)
BR (1) BR0100949A (pt)
CA (1) CA2339705A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
WO2004078131A2 (en) * 2003-03-01 2004-09-16 Symyx Technologies, Inc. Evaluating effects of exposure conditions on drug samples over time
CN1886152A (zh) * 2003-11-14 2006-12-27 阿尔萨公司 在药物辐射赋形剂制剂中药物氧化的最小化
US20070128285A1 (en) * 2005-07-12 2007-06-07 Chikara Jin Pharmaceutical composition for oral administration
US20090062909A1 (en) * 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
EP1909973B1 (en) 2005-07-15 2018-08-22 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
WO2007127363A2 (en) 2006-04-26 2007-11-08 Micell Technologies, Inc. Coatings containing multiple drugs
US8636767B2 (en) 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
WO2008086369A1 (en) 2007-01-08 2008-07-17 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
WO2008148013A1 (en) * 2007-05-25 2008-12-04 Micell Technologies, Inc. Polymer films for medical device coating
NZ588549A (en) 2008-04-17 2013-05-31 Micell Technologies Inc Stents having bioabsorbable layers
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
CA2756388C (en) * 2009-03-23 2015-10-27 Micell Technologies, Inc. Biodegradable polymers with low acidic impurity
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
CA2759015C (en) 2009-04-17 2017-06-20 James B. Mcclain Stents having controlled elution
WO2011097103A1 (en) 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
EP2560576B1 (en) 2010-04-22 2018-07-18 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN105307597A (zh) 2013-03-12 2016-02-03 脉胜医疗技术公司 可生物吸收的生物医学植入物
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
KR20180059584A (ko) 2013-05-15 2018-06-04 미셀 테크놀로지즈, 인코포레이티드 생흡수성 생체의학적 임플란트
US10391178B2 (en) * 2014-03-21 2019-08-27 Mylan Laboratories Limited Premix of crystalline raltegravir potassium salt and a process for the preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7400862A (en) * 1974-01-22 1975-07-24 Cornelis Moerman Dr Anti tumour compsns. - contain vitamins E and A and ferrous salts
GB1518364A (en) 1976-05-05 1978-07-19 Beecham Group Ltd Pharmaceutical composition
US5002779A (en) * 1989-11-07 1991-03-26 The Procter & Gamble Company Dry stable chocolate beverage containing iron and vitamin C
RU2080114C1 (ru) * 1994-06-21 1997-05-27 Акционерное общество закрытого типа "Фармакор" Препарат для лечения туберкулеза
CN1116927A (zh) * 1994-08-16 1996-02-21 湛江制药厂 氨基酸全营养素及其生产工艺
EP1007077B1 (en) * 1997-01-13 2009-10-07 Emory University Glutathione for the treatment of influenza infection
US5817047A (en) * 1997-03-17 1998-10-06 The Procter & Gamble Company Tampon and method of making same

Also Published As

Publication number Publication date
EP1145719A3 (en) 2001-11-14
US6423351B2 (en) 2002-07-23
US20020183392A1 (en) 2002-12-05
EP1145719A2 (en) 2001-10-17
CA2339705A1 (en) 2001-09-10
US6767558B2 (en) 2004-07-27
JP2001261577A (ja) 2001-09-26
US20010047034A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
BR0100949A (pt) Inibição da degradação oxidativa de formulaçõesfarmacêuticas
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
ES2137456T3 (es) Agente de tratamiento de las enfermedades hepato-biliares.
AR030185A1 (es) Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
BR9611802A (pt) Composições farmacêuticas
DK1313467T3 (da) Hidtil ukendte farmaceutiske præparater til indgivelse af N-0923
TW200718418A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
BR0212475A (pt) Composições farmacêuticas
BR0115965A (pt) Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
IT1320080B1 (it) Composizione per uso farmaceutico o dietetico.
ID18079A (id) Komposisi farmasi yang mengandung bahan pemercepat osteogenesis
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
PL1893237T3 (pl) Kompozycja farmaceutyczna zawierająca elastomer poliorganosiloksanowy i solubilizowany składnik aktywny
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
DK1414467T3 (da) Topisk behandling af mastalgi
BRPI0411702A (pt) uso de ácido hialurÈnico para preparar composições para o tratamento de aftas da cavidade oral
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009.